Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
VABYSMO is indicated for the treatment of adult patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).
.
Vial Prescribing Information
Pre-Filled Syringe Prescribing Information
Links:
Vabysmo in nAMD
Vabysmo in nAMD Real Word Data
Make VABYSMO your first choice in nAMD
Harness real-world impact for your service and patients in nAMD
nAMD
Uncover how VABYSMO improves anatomical and visual outcomes in nAMD, and offers extended treatment intervals to support both your service and patients
Prescribing information can be found using the buttons at the top of this page.
Real-world data, real-world impact
Discover how VABYSMO improves visual and anatomical outcomes in treatment-naive patients with nAMD over 1 year in the Moorfields Experience.
Prescribing information can be found using the buttons at the top of this page.
Links:
Vabysmo in nAMD
Vabysmo in nAMD: Real-World Data
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.
